Exact Sciences enrolls first patient in multi-cancer early detection study
- Exact Sciences has enrolled the first patient in its Multi-Cancer Early Detection (MCED) Falcon Registry Real-World Evidence study.
- The study will enroll up to 25,000 patients over five years to evaluate the clinical performance and impact of MCED testing.
- The U.S. FDA has authorized an investigational device exemption (IDE) for the MCED test, allowing its use in the study.
- Data will be collected from both the study cohort and a comparator cohort of up to 50,000 patients receiving standard care.
Read more
BerGenBio collaborates with Tempus to potentially accelerate development in STK11m non-small cell lung cancer
- BerGenBio partners with Tempus to advance bemcentinib in 1L NSCLC patients with STK11 mutations.
- The BGBC016 Phase 1b/2a trial assesses bemcentinib with standard care in STK11m patients.
- Tempus provides real-world clinical and molecular data to establish a synthetic control for the study.
- Insights from the study will be presented to regulatory agencies for further development of bemcentinib.
Read more
Inocras enters agreement with researchers at Broad Institute on whole genome cancer research project
- Inocras partners with the Broad Institute of MIT and Harvard for a joint analysis of whole-genome sequencing data from cancer.
- The project will be led by renowned cancer genomics experts Gad Getz and Youngseok Ju.
- The collaboration aims to uncover novel insights in cancer genomics to advance precision medicine.
- Inocras will serve as the major research collaborator and sponsor of this initiative.
Read more
InnoCare releases 2024 interim results and business highlights
- Furmonertinib shows preliminary efficacy in advanced non-small cell lung cancer (NSCLC) trials.
- ICP-189, a potential first-in-class SHP2 inhibitor, demonstrates significant anti-tumor effects in KRASG12C mutation and EGFR over-expression models.
- Orelabrutinib achieves proof of concept for primary immune thrombocytopenia purpura (ITP) and shows positive results in Phase IIa trial for systemic lupus erythematosus (SLE).
- ICP-332 demonstrates outstanding efficacy and safety in Phase II study for moderate-to-severe atopic dermatitis (AD); Phase III trial to start in Q4 2024.
Read more
